Hypomethylating agent combined with chemotherapy regimen

This page covers all Hypomethylating agent combined with chemotherapy regimen drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting DNA methyltransferase (DNMT), DNA methyltransferase (DNMT); also targets topoisomerase II and DNA synthesis, DNA methyltransferase (decitabine component); CD20, topoisomerase II, microtubule dynamics (R-CHOP components).

Targets

DNA methyltransferase (DNMT) · DNA methyltransferase (DNMT); also targets topoisomerase II and DNA synthesis · DNA methyltransferase (decitabine component); CD20, topoisomerase II, microtubule dynamics (R-CHOP components)

Phase 3 pipeline (3)

• Decitabine plus HAAG regimen · The First Affiliated Hospital of Soochow University · Oncology
  Decitabine plus HAAG (low-dose cytarabine, aclarubicin, amsacrine, and G-CSF) combines DNA methyltransferase inhibition with intensive chemotherapy to induce differentiation and apoptosis in leukemic cells.
• Decitabine combined with HAAG Regimen · The First Affiliated Hospital of Soochow University · Oncology
  Decitabine inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes, combined with HAAG chemotherapy (cytarabine, aclarubicin, amsacrine, granulocyte colony-stimulating factor) to enhance cytotoxic effects in hematologic malignancies.
• Decitabine in combination with R-CHOP · Second Affiliated Hospital of Nanchang University · Oncology
  Decitabine inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes, while R-CHOP chemotherapy directly kills lymphoma cells through multiple mechanisms.